File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza
  • Basic View
  • Metadata View
  • XML View
TitleHigh titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza
 
AuthorsTo, KKW1
Zhang, AJX1
Hung, IFN1
Xu, T1
Ip, WCT1
Wong, RTY1
Ng, JCK1
Chan, JFW1
Chan, KH1
Yuen, KY1
 
Issue Date2012
 
PublisherAmerican Society for Microbiology. The Journal's web site is located at http://cdli.asm.org/
 
CitationClinical And Vaccine Immunology, 2012, v. 19 n. 7, p. 1012-1018 [How to Cite?]
DOI: http://dx.doi.org/10.1128/CVI.00081-12
 
AbstractThe importance of neutralizing antibody in protection against influenza virus is well established, but the role of the early antibody response during the initial stage of infection in affecting the severity of disease is unknown. The 2009 influenza pandemic provided a unique opportunity for study because most patients lacked preexisting neutralizing antibody. In this study, we compared the antibody responses of 52 patients with severe or mild disease, using sera collected at admission. A microneutralization (MN) assay was used to detect neutralizing antibody. We also developed an enzyme-linked immunosorbent assay (ELISA) which detects both neutralizing and nonneutralizing antibodies against viral antigens from a split-virion inactivated monovalent influenza virus vaccine. While the MN titers were not significantly different between the two groups (P = 0.764), the ELISA titer and ELISA/MN titer ratio were significantly higher for patients with severe disease than for those with mild disease (P = 0.004 and P = 0.011, respectively). This finding suggested that in patients with severe disease, a larger proportion of serum antibodies were antibodies with no detectable neutralizing activity. The antibody avidity was also significantly higher in patients with severe disease than in those with mild disease (P < 0.05). Among patients with severe disease, those who required positive pressure ventilation (PPV) had significantly higher ELISA titers than those who did not require PPV (P < 0.05). Multivariate analysis showed that the ELISA titer and antibody avidity were independently associated with severe disease. Higher titers of nonneutralizing antibody with higher avidity at the early stage of influenza virus infection may be associated with worse clinical severity and poorer outcomes. Copyright © 2012, American Society for Microbiology. All Rights Reserved.
 
ISSN1556-6811
2012 Impact Factor: 2.598
2012 SCImago Journal Rankings: 0.938
 
DOIhttp://dx.doi.org/10.1128/CVI.00081-12
 
PubMed Central IDPMC3393364
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorTo, KKW
 
dc.contributor.authorZhang, AJX
 
dc.contributor.authorHung, IFN
 
dc.contributor.authorXu, T
 
dc.contributor.authorIp, WCT
 
dc.contributor.authorWong, RTY
 
dc.contributor.authorNg, JCK
 
dc.contributor.authorChan, JFW
 
dc.contributor.authorChan, KH
 
dc.contributor.authorYuen, KY
 
dc.date.accessioned2012-09-05T05:32:44Z
 
dc.date.available2012-09-05T05:32:44Z
 
dc.date.issued2012
 
dc.description.abstractThe importance of neutralizing antibody in protection against influenza virus is well established, but the role of the early antibody response during the initial stage of infection in affecting the severity of disease is unknown. The 2009 influenza pandemic provided a unique opportunity for study because most patients lacked preexisting neutralizing antibody. In this study, we compared the antibody responses of 52 patients with severe or mild disease, using sera collected at admission. A microneutralization (MN) assay was used to detect neutralizing antibody. We also developed an enzyme-linked immunosorbent assay (ELISA) which detects both neutralizing and nonneutralizing antibodies against viral antigens from a split-virion inactivated monovalent influenza virus vaccine. While the MN titers were not significantly different between the two groups (P = 0.764), the ELISA titer and ELISA/MN titer ratio were significantly higher for patients with severe disease than for those with mild disease (P = 0.004 and P = 0.011, respectively). This finding suggested that in patients with severe disease, a larger proportion of serum antibodies were antibodies with no detectable neutralizing activity. The antibody avidity was also significantly higher in patients with severe disease than in those with mild disease (P < 0.05). Among patients with severe disease, those who required positive pressure ventilation (PPV) had significantly higher ELISA titers than those who did not require PPV (P < 0.05). Multivariate analysis showed that the ELISA titer and antibody avidity were independently associated with severe disease. Higher titers of nonneutralizing antibody with higher avidity at the early stage of influenza virus infection may be associated with worse clinical severity and poorer outcomes. Copyright © 2012, American Society for Microbiology. All Rights Reserved.
 
dc.description.naturelink_to_OA_fulltext
 
dc.identifier.citationClinical And Vaccine Immunology, 2012, v. 19 n. 7, p. 1012-1018 [How to Cite?]
DOI: http://dx.doi.org/10.1128/CVI.00081-12
 
dc.identifier.doihttp://dx.doi.org/10.1128/CVI.00081-12
 
dc.identifier.epage1018
 
dc.identifier.hkuros203192
 
dc.identifier.issn1556-6811
2012 Impact Factor: 2.598
2012 SCImago Journal Rankings: 0.938
 
dc.identifier.issue7
 
dc.identifier.pmcidPMC3393364
 
dc.identifier.pmid22573737
 
dc.identifier.scopuseid_2-s2.0-84863558273
 
dc.identifier.spage1012
 
dc.identifier.urihttp://hdl.handle.net/10722/163507
 
dc.identifier.volume19
 
dc.languageeng
 
dc.publisherAmerican Society for Microbiology. The Journal's web site is located at http://cdli.asm.org/
 
dc.publisher.placeUnited States
 
dc.relation.ispartofClinical and Vaccine Immunology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsClinical and Vaccine Immunology. Copyright © American Society for Microbiology.
 
dc.rightsCopyright © American Society for Microbiology, [Clinical and Vaccine Immunology, 2012, v. 19 n. 7, p. 1012-1018]
 
dc.subject.meshAntibodies, Neutralizing - blood
 
dc.subject.meshAntibodies, Viral - blood
 
dc.subject.meshAntibody Affinity
 
dc.subject.meshInfluenza A Virus, H1N1 Subtype - immunology
 
dc.subject.meshInfluenza, Human - immunology - pathology - virology
 
dc.titleHigh titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>To, KKW</contributor.author>
<contributor.author>Zhang, AJX</contributor.author>
<contributor.author>Hung, IFN</contributor.author>
<contributor.author>Xu, T</contributor.author>
<contributor.author>Ip, WCT</contributor.author>
<contributor.author>Wong, RTY</contributor.author>
<contributor.author>Ng, JCK</contributor.author>
<contributor.author>Chan, JFW</contributor.author>
<contributor.author>Chan, KH</contributor.author>
<contributor.author>Yuen, KY</contributor.author>
<date.accessioned>2012-09-05T05:32:44Z</date.accessioned>
<date.available>2012-09-05T05:32:44Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Clinical And Vaccine Immunology, 2012, v. 19 n. 7, p. 1012-1018</identifier.citation>
<identifier.issn>1556-6811</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/163507</identifier.uri>
<description.abstract>The importance of neutralizing antibody in protection against influenza virus is well established, but the role of the early antibody response during the initial stage of infection in affecting the severity of disease is unknown. The 2009 influenza pandemic provided a unique opportunity for study because most patients lacked preexisting neutralizing antibody. In this study, we compared the antibody responses of 52 patients with severe or mild disease, using sera collected at admission. A microneutralization (MN) assay was used to detect neutralizing antibody. We also developed an enzyme-linked immunosorbent assay (ELISA) which detects both neutralizing and nonneutralizing antibodies against viral antigens from a split-virion inactivated monovalent influenza virus vaccine. While the MN titers were not significantly different between the two groups (P = 0.764), the ELISA titer and ELISA/MN titer ratio were significantly higher for patients with severe disease than for those with mild disease (P = 0.004 and P = 0.011, respectively). This finding suggested that in patients with severe disease, a larger proportion of serum antibodies were antibodies with no detectable neutralizing activity. The antibody avidity was also significantly higher in patients with severe disease than in those with mild disease (P &lt; 0.05). Among patients with severe disease, those who required positive pressure ventilation (PPV) had significantly higher ELISA titers than those who did not require PPV (P &lt; 0.05). Multivariate analysis showed that the ELISA titer and antibody avidity were independently associated with severe disease. Higher titers of nonneutralizing antibody with higher avidity at the early stage of influenza virus infection may be associated with worse clinical severity and poorer outcomes. Copyright &#169; 2012, American Society for Microbiology. All Rights Reserved.</description.abstract>
<language>eng</language>
<publisher>American Society for Microbiology. The Journal&apos;s web site is located at http://cdli.asm.org/</publisher>
<relation.ispartof>Clinical and Vaccine Immunology</relation.ispartof>
<rights>Clinical and Vaccine Immunology. Copyright &#169; American Society for Microbiology.</rights>
<rights>Copyright &#169; American Society for Microbiology, [Clinical and Vaccine Immunology, 2012, v. 19 n. 7, p. 1012-1018]</rights>
<subject.mesh>Antibodies, Neutralizing - blood</subject.mesh>
<subject.mesh>Antibodies, Viral - blood</subject.mesh>
<subject.mesh>Antibody Affinity</subject.mesh>
<subject.mesh>Influenza A Virus, H1N1 Subtype - immunology</subject.mesh>
<subject.mesh>Influenza, Human - immunology - pathology - virology</subject.mesh>
<title>High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza</title>
<type>Article</type>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.doi>10.1128/CVI.00081-12</identifier.doi>
<identifier.pmid>22573737</identifier.pmid>
<identifier.pmcid>PMC3393364</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-84863558273</identifier.scopus>
<identifier.hkuros>203192</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84863558273&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>19</identifier.volume>
<identifier.issue>7</identifier.issue>
<identifier.spage>1012</identifier.spage>
<identifier.epage>1018</identifier.epage>
<publisher.place>United States</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/163507/1/re01.htm</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong